These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32108756)

  • 21. Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.
    Buller HR; Halperin J; Hankey GJ; Pillion G; Prins MH; Raskob GE
    J Thromb Haemost; 2014 Jun; 12(6):824-30. PubMed ID: 24597472
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: A study-level meta-analysis of phase III randomized trials.
    Patti G; Di Gioia G; Cavallari I; Nenna A
    Diabetes Metab Res Rev; 2017 Mar; 33(3):. PubMed ID: 28029216
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators.
    Carnicelli AP; Hong H; Giugliano RP; Connolly SJ; Eikelboom J; Patel MR; Wallentin L; Morrow DA; Wojdyla D; Hua K; Hohnloser SH; Oldgren J; Ruff CT; Piccini JP; Lopes RD; Alexander JH; Granger CB;
    Am Heart J; 2021 Mar; 233():48-58. PubMed ID: 33296688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Long-term health benefits of stroke prevention with apixaban versus vitamin K antagonist warfarin in patients with non-valvular atrial fibrillation in Germany: a population-based modelling study.
    Himmler S; Müller M; Ostwald D; Seddik A; Basic E; Hradetzky E
    Expert Rev Pharmacoecon Outcomes Res; 2019 Apr; 19(2):223-230. PubMed ID: 30295561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of Major Bleeding in Patients With Atrial Fibrillation Treated With Non-Vitamin K Antagonist Oral Anticoagulants Compared With Warfarin in Clinical Practice (from Phase II of the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation [ORBIT-AF II]).
    Steinberg BA; Simon DN; Thomas L; Ansell J; Fonarow GC; Gersh BJ; Kowey PR; Mahaffey KW; Peterson ED; Piccini JP;
    Am J Cardiol; 2017 May; 119(10):1590-1595. PubMed ID: 28363354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation With Hypertrophic Cardiomyopathy: A Nationwide Cohort Study.
    Jung H; Yang PS; Jang E; Yu HT; Kim TH; Uhm JS; Kim JY; Pak HN; Lee MH; Joung B; Lip GYH
    Chest; 2019 Feb; 155(2):354-363. PubMed ID: 30472021
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Trends in oral anticoagulant choice for acute stroke patients with nonvalvular atrial fibrillation in Japan: the SAMURAI-NVAF study.
    Toyoda K; Arihiro S; Todo K; Yamagami H; Kimura K; Furui E; Terasaki T; Shiokawa Y; Kamiyama K; Takizawa S; Okuda S; Okada Y; Kameda T; Nagakane Y; Hasegawa Y; Mochizuki H; Ito Y; Nakashima T; Takamatsu K; Nishiyama K; Kario K; Sato S; Koga M;
    Int J Stroke; 2015 Aug; 10(6):836-42. PubMed ID: 25581108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Utilization of oral anticoagulants in Korean nonvalvular atrial fibrillation patients.
    Song HY; Son KB; Shin JY; Bae S
    Int J Clin Pharm; 2019 Dec; 41(6):1434-1441. PubMed ID: 31522377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is decreased stroke severity in patients with atrial fibrillation receiving non-vitamin K oral anticoagulant treatment the coup de grâce for warfarin?
    Katsanos AH
    Eur J Neurol; 2020 Mar; 27(3):411-412. PubMed ID: 31876019
    [No Abstract]   [Full Text] [Related]  

  • 30. Contra: 'Warfarin should be the drug of choice for thromboprophylaxis in elderly patients with atrial fibrillation'. Caveats regarding use of oral anticoagulant therapy among elderly patients with atrial fibrillation.
    Hylek EM
    Thromb Haemost; 2008 Jul; 100(1):16-7. PubMed ID: 18612532
    [No Abstract]   [Full Text] [Related]  

  • 31. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients With Impaired Liver Function: A Retrospective Cohort Study.
    Wang CL; Wu VC; Kuo CF; Chu PH; Tseng HJ; Wen MS; Chang SH
    J Am Heart Assoc; 2018 Aug; 7(15):e009263. PubMed ID: 30371232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized controlled trials of new oral anticoagulants for stroke prevention in atrial fibrillation.
    Liew A; Eikelboom JW; O'Donnell M
    Curr Opin Cardiol; 2012 Jul; 27(4):331-9. PubMed ID: 22573171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel oral anticoagulants for stroke prevention in patients with atrial fibrillation.
    Berman JP; Halperin JL
    Hosp Pract (1995); 2013 Feb; 41(1):37-48. PubMed ID: 23466966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early administration of non-vitamin K antagonist oral anticoagulants for acute ischemic stroke patients with atrial fibrillation in comparison with warfarin mostly combined with heparin.
    Nomura E; Ohshita T; Imamura E; Wakabayashi S; Kajikawa H; Hosomi N; Matsumoto M
    Circ J; 2015; 79(4):862-6. PubMed ID: 25736910
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness and safety of non-vitamin-K antagonist oral anticoagulants versus warfarin in atrial fibrillation patients with thrombocytopenia.
    Wang CL; Wu VC; Lee CH; Kuo CF; Chen YL; Chu PH; Chen SW; Wen MS; See LC; Chang SH
    J Thromb Thrombolysis; 2019 May; 47(4):512-519. PubMed ID: 30565148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Effectiveness of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Atrial Fibrillation and Anemia: A Retrospective Cohort Study.
    Wang CL; Wu VC; Huang YT; Kuo CF; Chu PH; Chen YL; Wen MS; Chang SH
    J Am Heart Assoc; 2019 May; 8(9):e012029. PubMed ID: 31020896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quality of life and patient satisfaction in patients with atrial fibrillation on stable vitamin K antagonist treatment or switched to a non-vitamin K antagonist oral anticoagulant during a 1-year follow-up: A PREFER in AF Registry substudy.
    De Caterina R; Brüggenjürgen B; Darius H; Köhler S; Lucerna M; Pecen L; Renda G; Schilling RJ; Schliephacke T; Zamorano JL; Le Heuzey JY; Kirchhof P
    Arch Cardiovasc Dis; 2018 Feb; 111(2):74-84. PubMed ID: 28942115
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: a French payer perspective.
    Chevalier J; Delaitre O; Hammès F; de Pouvourville G
    Arch Cardiovasc Dis; 2014; 107(6-7):381-90. PubMed ID: 24973113
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-vitamin K antagonist oral anticoagulants compared with warfarin at different levels of INR control in atrial fibrillation: A meta-analysis of randomized trials.
    Carmo J; Ferreira J; Costa F; Carmo P; Cavaco D; Carvalho S; Morgado F; Adragão P; Mendes M
    Int J Cardiol; 2017 Oct; 244():196-201. PubMed ID: 28679480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.